Insider · CIK 0001573785

Davidson Michael H.

Reports to the SEC for 6 companies · NAARDEN

sec.gov

Transactions

Companies

Filings

CIK

0001573785

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-14	NAMSNewAmsterdam Pharma Co N.V.P Purchase	Director, Chief Executive Officer	PPurchase	+10K sh	$22.65	+$227K	792,923
2026-06-10	BIOABioAge Labs, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22K sh	—	—	22,000
2026-03-02	NAMSNewAmsterdam Pharma Co N.V.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+444K sh	—	—	617,851
2026-03-02	NAMSNewAmsterdam Pharma Co N.V.S Sale	Director, Chief Executive Officer	SSale	−444K sh	$33.25	−$14.8M	174,144
2026-03-02	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−444K sh	—	—	239,267
2026-02-26	NAMSNewAmsterdam Pharma Co N.V.S Sale	Director, Chief Executive Officer	SSale	−165K sh	$33.63	−$5.56M	477,783
2026-02-26	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−183K sh	—	—	682,974
2026-02-26	NAMSNewAmsterdam Pharma Co N.V.S Sale	Director, Chief Executive Officer	SSale	−17.9K sh	$34.44	−$617K	174,144
2026-02-26	NAMSNewAmsterdam Pharma Co N.V.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+183K sh	—	—	643,191
2026-02-25	NAMSNewAmsterdam Pharma Co N.V.S Sale	Director, Chief Executive Officer	SSale	−46.5K sh	$35.11	−$1.63M	471,595
2026-02-25	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−58.3K sh	—	—	866,306
2026-02-25	NAMSNewAmsterdam Pharma Co N.V.S Sale	Director, Chief Executive Officer	SSale	−1,300 sh	$36.68	−$47.7K	459,859
2026-02-25	NAMSNewAmsterdam Pharma Co N.V.S Sale	Director, Chief Executive Officer	SSale	−10.4K sh	$35.96	−$375K	461,159
2026-02-25	NAMSNewAmsterdam Pharma Co N.V.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+58.3K sh	—	—	518,112
2026-02-24	NAMSNewAmsterdam Pharma Co N.V.S Sale	Director, Chief Executive Officer	SSale	−3,161 sh	$36.46	−$115K	459,859
2026-02-24	NAMSNewAmsterdam Pharma Co N.V.S Sale	Director, Chief Executive Officer	SSale	−61.5K sh	$36.13	−$2.22M	463,020
2026-02-24	NAMSNewAmsterdam Pharma Co N.V.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+64.7K sh	—	—	524,567
2026-02-24	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−64.7K sh	—	—	924,559
2026-01-09	TENXTENAX THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2026-01-07	NAMSNewAmsterdam Pharma Co N.V.A Award	Director, Chief Executive Officer	AAward	+81K sh	—	—	459,859
2026-01-07	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+364K sh	—	—	364,000
2026-01-07	NAMSNewAmsterdam Pharma Co N.V.S Sale	Director, Chief Executive Officer	SSale	−11.6K sh	—	—	378,859
2025-07-01	TENXTENAX THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+80K sh	—	—	80,000
2025-06-05	BIOABioAge Labs, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22K sh	—	—	22,000
2025-03-26	NAMSNewAmsterdam Pharma Co N.V.S Sale	Director, Chief Executive Officer	SSale	−12.3K sh	—	—	390,441
2025-03-26	NAMSNewAmsterdam Pharma Co N.V.A Award	Director, Chief Executive Officer	AAward	+31K sh	—	—	364,305
2025-03-26	NAMSNewAmsterdam Pharma Co N.V.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+38.4K sh	—	—	402,699
2025-03-26	NAMSNewAmsterdam Pharma Co N.V. · Restricted Stock UnitA Award	Director, Chief Executive Officer	AAward	+38.4K sh	—	—	38,394
2025-03-26	NAMSNewAmsterdam Pharma Co N.V. · Restricted Stock UnitM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−38.4K sh	—	—	0
2025-01-07	NAMSNewAmsterdam Pharma Co N.V.A Award	Director, Chief Executive Officer	AAward	+124K sh	—	—	123,529
2025-01-06	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+670K sh	—	—	670,467
2025-01-02	SLNSilence Therapeutics plc · Share Option (Right to Buy)A Award	Director	AAward	+48K sh	—	—	48,000
2024-12-10	TENXTENAX THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+100K sh	—	—	100,000
2024-10-09	NAMSNewAmsterdam Pharma Co N.V. · Warrant (right to buy)G Gift	Director, Chief Executive Officer	GGift	−15K sh	$11.50	−$173K	85,000
2024-09-25	BIOABioAge Labs, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2024-08-20	NAMSNewAmsterdam Pharma Co N.V.P Purchase	Director, Chief Executive Officer	PPurchase	+5,000 sh	$16.27	+$81.4K	209,784
2024-08-08	TENXTENAX THERAPEUTICS, INC. · WarrantP Purchase	Director	PPurchase	+25K sh	—	—	25,000
2024-08-08	TENXTENAX THERAPEUTICS, INC.P Purchase	Director	PPurchase	+2,500 sh	—	—	2,881
2024-08-08	TENXTENAX THERAPEUTICS, INC. · Pre-Funded WarrantP Purchase	Director	PPurchase	+47.5K sh	—	—	47,500
2024-06-20	NAMSNewAmsterdam Pharma Co N.V.P Purchase	Director, Chief Executive Officer	PPurchase	+5,000 sh	$17.26	+$86.3K	204,784
2024-03-26	BIOABioAge Labs, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+34K sh	—	—	33,986
2024-01-01	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+1.04M sh	—	—	1,039,939
2022-06-09	TENXTENAX THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+5,000 sh	—	—	5,000
2022-01-10	LSTALISATA THERAPEUTICS, INC.A Award	Director	AAward	+65.4K sh	—	—	209,753
2021-06-11	TENXTENAX THERAPEUTICS, INC.A Award	Director	AAward	+512K sh	—	—	606,645
2021-06-11	TENXTENAX THERAPEUTICS, INC. · Series B Preferred StockM Exercise/Conversion	Director	MExercise/Conversion	−512 sh	—	—	0
2021-06-10	TENXTENAX THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+6,250 sh	—	—	6,250
2021-01-11	LSTALISATA THERAPEUTICS, INC.A Award	Director	AAward	+37.7K sh	—	—	144,323
2020-09-09	LSTALISATA THERAPEUTICS, INC.P Purchase	Director	PPurchase	+55.5K sh	$1.80	+$99.9K	106,588
2020-07-28	LSTALISATA THERAPEUTICS, INC.A Award	Director	AAward	+51.1K sh	$2.35	+$120K	51,063

Recent filings

Accepted (ET)
Sep 154
Davidson Michael H.0001193125-26-391985
SEC(opens sec.gov)
Jun 124
Davidson Michael H.0001573785-26-000003
SEC(opens sec.gov)
Mar 24
Davidson Michael H.0001193125-26-085947
SEC(opens sec.gov)
Feb 264
Davidson Michael H.0001193125-26-078718
SEC(opens sec.gov)
Jan 134
Davidson Michael H.0001573785-26-000001
SEC(opens sec.gov)
Jan 94
Davidson Michael H.0001193125-26-009272
SEC(opens sec.gov)

Companies

Address

C/O NEWAMSTERDAM PHARMA COMPANY N.V. GOOIMEER 2-35

NAARDEN, 1411 DC